Quinn, Robert A.
Melnik, Alexey V.
Vrbanac, Alison
Fu, Ting
Patras, Kathryn A.
Christy, Mitchell P.
Bodai, Zsolt
Belda-Ferre, Pedro
Tripathi, Anupriya
Chung, Lawton K.
Downes, Michael
Welch, Ryan D.
Quinn, Melissa
Humphrey, Greg
Panitchpakdi, Morgan
Weldon, Kelly C.
Aksenov, Alexander
da Silva, Ricardo
Avila-Pacheco, Julian
Clish, Clary
Bae, Sena
Mallick, Himel
Franzosa, Eric A.
Lloyd-Price, Jason
Bussell, Robert
Thron, Taren
Nelson, Andrew T.
Wang, Mingxun
Leszczynski, Eric
Vargas, Fernando
Gauglitz, Julia M.
Meehan, Michael J.
Gentry, Emily
Arthur, Timothy D.
Komor, Alexis C.
Poulsen, Orit
Boland, Brigid S.
Chang, John T.
Sandborn, William J.
Lim, Meerana
Garg, Neha
Lumeng, Julie C.
Xavier, Ramnik J.
Kazmierczak, Barbara I.
Jain, Ruchi
Egan, Marie
Rhee, Kyung E.
Ferguson, David
Raffatellu, Manuela
Vlamakis, Hera
Haddad, Gabriel G.
Siegel, Dionicio
Huttenhower, Curtis
Mazmanian, Sarkis K.
Evans, Ronald M.
Nizet, Victor
Knight, Rob
Dorrestein, Pieter C.
Article History
Received: 6 July 2018
Accepted: 3 January 2020
First Online: 26 February 2020
Competing interests
: C.H. is on the scientific advisory board of Seres Therapeutics. M.W. is founder of, and A.A. is a consultant for, Ometa Laboratories LLC. P.C.D. and M.W. are consultants for Sirenas Therapeutics. W.J.S. consults for Abbvie, Allergan, Amgen, Arena Pharmaceuticals, Avexegen Therapeutics, BeiGene, Boehringer Ingelheim, Celgene, Celltrion, Conatus, Cosmo, Escalier Biosciences, Ferring, Forbion, Genentech, Gilead Sciences, Gossamer Bio, Incyte, Janssen, Kyowa Kirin Pharmaceutical Research, Landos Biopharma, Lilly, Oppilan Pharma, Otsuka, Pfizer, Progenity, Prometheus Biosciences (merger of Precision IBD and Prometheus Laboratories), Reistone, Ritter Pharmaceuticals, Robarts Clinical Trials (owned by Health Academic Research Trust, HART), Series Therapeutics, Shire, Sienna Biopharmaceuticals, Sigmoid Biotechnologies, Sterna Biologicals, Sublimity Therapeutics, Takeda, Theravance Biopharma, Tigenix, Tillotts Pharma, UCB Pharma, Ventyx Biosciences, Vimalan Biosciences and Vivelix Pharmaceuticals; and holds stock or stock options from BeiGene, Escalier Biosciences, Gossamer Bio, Oppilan Pharma, Prometheus Biosciences (merger of Precision IBD and Prometheus Laboratories), Progenity, Ritter Pharmaceuticals, Ventyx Biosciences and Vimalan Biosciences.